High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis

Journal of the American Society of Nephrology

Volumn 26, Issue 10, 2015, Pages 2534-2544

  Malluche, Hartmut H ^a   Blomquist, Gustav ^a   Monier Faugere, Marie Claude ^a   Cantor, Thomas L ^b   Davenport, Daniel L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Scantibodies Laboratory Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; BICARBONATE; DICKKOPF 1 PROTEIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHORUS; SCLEROSTIN;

ADULT; AGATSTON SCORE; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PREDICTIVE VALUE; RENAL REPLACEMENT THERAPY; VASCULAR CALCIFICATION;

CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; VASCULAR CALCIFICATION;

EID: 84942916271     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014070686     Document Type: Article

References (79)

1. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, Dias-Curto J, Malluche HH: Low bone volume-A risk factor for coronary calcifications in hemodialysis patients. Clin J Am Soc Nephrol 4: 450-455, 2009.
2. Asci G, Ok E, Savas R, Ozkahya M, Duman S, Toz H, Kayikcioglu M, Branscum AJ, Monier-Faugere MC, Herberth J, Malluche HH: The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transplant 26: 1010-1015, 2011.
3. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME: Association of changes in bone remodeling and coronary calcification in hemodialysis patients: A prospective study. Am J Kidney Dis 52: 1139-1150, 2008.
4. Filgueira A, Carvalho AB, Tomiyama C, Higa A, Rochitte CE, Santos RD, Canziani ME: Is coronary artery calcification associated with vertebral bone density in nondialyzed chronic kidney disease patients? Clin J Am Soc Nephrol 6: 1456-1462, 2011.
5. Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani ME: Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res 25: 499- 504, 2010.
6. US Renal Data System: USRDS 2008 Annual Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, NIH and NIDDK, 2008.
7. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J AmSoc Nephrol 16: 489-495, 2005.
8. Budoff MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, Demoss D, Nuguri V, Nabavi V, Ratakonda R, Berman DS, Raggi P: Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging 3: 1229-1236, 2010.
9. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002.
10. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002.
11. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB:Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl JMed 342: 1478-1483, 2000.
12. Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, Budoff M; CARE-2 Investigators: A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: The Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 51: 952-965, 2008.
13. Cauley JA, Zmuda JM, Wisniewski SR, Krishnaswami S, Palermo L, Stone KL, Black DM, Nevitt MC: Bone mineral density and prevalent vertebral fractures in men and women.Osteoporos Int 15: 32-37, 2004.
14. Hui SL, Slemenda CW, Johnston CC Jr.: Age and bonemass as predictors of fracture in a prospective study. J Clin Invest 81: 1804-1809, 1988.
15. Leib ES, Lewiecki EM, Binkley N, Hamdy RC; International Society for Clinical Densitometry: Official positions of the International Society for Clinical Densitometry. J Clin Densitom 7: 1-6, 2004.
16. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007.
17. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, HammLL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003.
18. Cianciolo G, LaManna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Colì L, Wratten M, Stefoni S: Coronary calcifications in end-stage renal disease patients: A new link between osteoprotegerin, diabetes and body mass index? Blood Purif 29: 13-22, 2010.
19. Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, Mühlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ: Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 101: 359-366, 2009.
20. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM; ADVANCE Study group: Study design and subject baseline characteristics in the ADVANCE Study: Effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 25: 1916-1923, 2010.
21. Oka M, Ohtake T, Mochida Y, Ishioka K, Maesato K, Moriya H, Hidaka S, Kobayashi S: Correlation of coronary artery calcification with prehemodialysis bicarbonate levels in patients on hemodialysis. Ther Apher Dial 16: 267-271, 2012.
22. Patsalas S, Eleftheriadis T, Spaia S, Theodoroglou H, Antoniadi G, Liakopoulos V, Passadakis P, Vayonas G, Vargemezis V: Thirty-month follow-up of coronary artery calcification in hemodialysis patients: Different roles for inflammation and abnormal calcium-phosphorous metabolism? Ren Fail 29: 623-629, 2007.
23. Pencak P, Czerwienska B, Ficek R, Wyskida K, Kujawa-Szewieczek A, Olszanecka-Glinianowicz M, Wiecek A, Chudek J: Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients. BMC Nephrol 14: 10, 2013.
24. Xiao DM, Wu Q, Fan WF, Ye XW, Niu JY, Gu Y: Effect of serum FGF-23, MGP and fetuin-A on calcium-phosphate metabolism in maintenance hemodialysis patients. Hemodial Int 17: 483-492, 2013.
25. Kurnatowska I, Grzelak P, Stefanczyk L, Nowicki M: Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. Nephrology (Carlton) 15: 184-189, 2010.
26. Mehrotra R, Budoff M, Hokanson JE, Ipp E, Takasu J, Adler S: Progression of coronary artery calcification in diabetics with and without chronic kidney disease. Kidney Int 68: 1258-1266, 2005.
27. Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJ: Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant 22: 3208-3213, 2007.
28. Stavroulopoulos A, Porter CJ, Pointon K, Monaghan JM, Roe SD, Cassidy MJ: Evolution of coronary artery calcification in patients with chronic kidney disease Stages 3 and 4, with and without diabetes. Nephrol Dial Transplant 26: 2582-2589, 2011.
29. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M; Chronic Renal Insufficiency Cohort Study Investigators: Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 83: 1159-1168, 2013.
30. Stompór T, Pasowicz M, Sulłowicz W, Dembinska-Kiec A, Janda K, Wójcik K, Tracz W, Zdzienicka A, Klimeczek P, Janusz-Grzybowska E: An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 41: 203-211, 2003.
31. Delaney JA, Jensky NE, Criqui MH, Whitt-Glover MC, Lima JA, Allison MA: The association between physical activity and both incident coronary artery calcification and ankle brachial index progression: The multi-ethnic study of atherosclerosis. Atherosclerosis 230: 278-283, 2013.
32. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1-S201, 2003.
33. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113[Suppl]: S1-S130, 2009.
34. Malluche HH, Davenport DL, Cantor T, Monier-Faugere MC: Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J AmSoc Nephrol 9: 1254-1262, 2014.
35. Iimori S, Mori Y, Akita W, Kuyama T, Takada S, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y: Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-A single-center cohort study. Nephrol Dial Transplant 27: 345-351, 2012.
36. Jamal S, Cheung AM, West S, Lok C: Bone mineral density by DXA and HR pQCT can discriminate fracture status in men and women with stages 3 to 5 chronic kidney disease. Osteoporos Int 23: 2805-2813, 2012.
37. Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB: Bone metabolism, vascular calcifications and mortality: Associations beyond mere coincidence. J Nephrol 18: 458-463, 2005.
38. Bellasi A, Zona S, Orlando G, Carli F, Ligabue G, Rochira V, Santoro A, Mussini C, Guaraldi G, Raggi P: Inverse correlation between vascular calcification and bone mineral density in human immunodeficiency virus-infected patients. Calcif Tissue Int 93: 413-418, 2013.
39. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW: Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif Tissue Int 68: 271-276, 2001.
40. Lee HT, Shin J, Lim YH, Kim BK, Kim YT, Lee JU, Hong S, Song SY, Cho SH: The relationship between coronary artery calcification and bone mineral density in patients according to their metabolic syndrome status. Korean Circ J 41: 76-82, 2011.
41. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89: 4246- 4253, 2004.
42. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA; European Uremic Toxin (EUTox) Work Group: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23: 2017-2025, 2012.
43. Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, Kuma K: Fibroblast growth factor 23 is associatedwith carotid artery calcification in chronic kidney disease patients not undergoing dialysis: A crosssectional study. BMC Nephrol 14: 22, 2013.
44. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, Hawa G, Chapurlat R, Szulc P: Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: The STRAMBOstudy. J Clin EndocrinolMetab 97: E575-E583, 2012.
45. Balci M, Kirkpantur A, Gulbay M, Gurbuz OA: Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 14: 425-432, 2010.
46. Ozkok A, Kekik C, Karahan GE, Sakaci T, Ozel A, Unsal A, Yildiz A: FGF- 23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol 14: 241, 2013.
47. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR: Association of serum phosphate with vascular and valvular calcification in moderate CKD. J AmSoc Nephrol 20: 381-387, 2009.
48. Giachelli CM: Mechanisms of vascular calcification in uremia. Semin Nephrol 24: 401-402, 2004.
49. Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED: Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 26: 945-951, 2011.
50. Bellasi A, Kooienga L, Block GA, Veledar E, Spiegel DM, Raggi P: How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis? J Nephrol 22: 255-262, 2009.
51. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401, 1996.
52. Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE: FGF-23 and the progression of coronary arterial calcification in patients newto dialysis. Clin J Am Soc Nephrol 7: 2017-2022, 2012.
53. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K: Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 38: 64-69, 2001.
54. Bellasi A, Veledar E, Ferramosca E, Ratti C, Block G, Raggi P: Markers of vascular disease do not differ in black and white hemodialysis patients despite a different risk profile. Atherosclerosis 197: 242- 249, 2008.
55. Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ, Allison MA: Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 311: 271-278, 2014.
56. Nickolas TL: The utility of circulating markers to predict bone loss across the CKD spectrum. Clin J Am Soc Nephrol 9: 1160-1162, 2014.
57. Griffin LM, Kalkwarf HJ, Zemel BS, Shults J, Wetzsteon RJ, Strife CF, Leonard MB: Assessment of dual-energy X-ray absorptiometry measures of bone health in pediatric chronic kidney disease. Pediatr Nephrol 27: 1139-1148, 2012.
58. Jamal SA, Hayden JA, Beyene J: Low bone mineral density and fractures in long-term hemodialysis patients: A meta-analysis. Am J Kidney Dis 49: 674-681, 2007.
59. Jamal SA, West SL, Miller PD: Fracture risk assessment in patients with chronic kidney disease. Osteoporos Int 23: 1191-1198, 2012.
60. Leonard MB: A structural approach to the assessment of fracture risk in children and adolescents with chronic kidney disease. Pediatr Nephrol 22: 1815-1824, 2007.
61. Nickolas TL, Leonard MB, Shane E: Chronic kidney disease and bone fracture: A growing concern. Kidney Int 74: 721-731, 2008.
62. Malluche HH, Mawad HW, Monier-Faugere MC: Renal osteodystrophy in the first decade of the newmillennium: Analysis of 630 bone biopsies in black and white patients. J BoneMiner Res 26: 1368-1376, 2011.
63. Fishman WH: Alkaline phosphatase isozymes: Recent progress. Clin Biochem 23: 99-104, 1990.
64. Hale LV, Galvin RJ, Risteli J, Ma YL, Harvey AK, Yang X, Cain RL, Zeng Q, Frolik CA, Sato M, Schmidt AL, Geiser AG: PINP: A serum biomarker of bone formation in the rat. Bone 40: 1103-1109, 2007.
65. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK: Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res 15: 1337-1345, 2000.
66. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, MuzylakM, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD: Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284: 10890- 10900, 2009.
67. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA: Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276, 2003.
68. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N: Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113-24117, 2003.
69. Padhi D, Jang G, Stouch B, Fang L, Posvar E: Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26: 19-26, 2011.
70. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, Shaughnessy JD Jr.: The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525, 2009.
71. Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, PatelN, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371- 379, 2009.
72. Morvan F, Boulukos K, Clément-Lacroix P, Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G: Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J BoneMiner Res 21: 934-945, 2006.
73. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315, 2006.
74. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD: Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 192: 261-267, 2007.
75. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49, 2006.
76. Erlichman M, Holohan TV: Bone densitometry: Patients with end-stage renal disease. Health Technol Assess (Rockv) 8: 1-27, 1996.
77. Malluche HH, Arnala I, Faugere MC: Values of noninvasive techniques in predicting bone histology. Ann Chir Gynaecol 77: 246-250, 1988.
78. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr., Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J AmColl Cardiol 15: 827-832, 1990.
79. Hokanson JE, MacKenzie T, Kinney G, Snell-Bergeon JK, Dabelea D, Ehrlich J, Eckel RH, Rewers M: Evaluating changes in coronary artery calcium: An analytic method that accounts for interscan variability. AJR Am J Roentgenol 182: 1327-1332, 2004.